报价延迟最少15分钟:2026/04/24 21:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.26 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.72/6.50
|
|
企业价值
10.87B
|
| 资产负债 |
|
每股账面净值
2.89
|
| 现金流量 |
|
现金流量率
0.31
|
| 损益表 |
|
收益
6.22B
|
|
每股收益
23.63
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments. |
